Logo image of BNN.DE

BRAIN BIOTECH AG (BNN.DE) Stock Fundamental Analysis

FRA:BNN - Deutsche Boerse Ag - DE0005203947 - Common Stock - Currency: EUR

1.94  +0.06 (+3.19%)

Fundamental Rating

2

Overall BNN gets a fundamental rating of 2 out of 10. We evaluated BNN against 67 industry peers in the Chemicals industry. BNN may be in some trouble as it scores bad on both profitability and health. BNN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BNN had negative earnings in the past year.
In the past year BNN has reported a negative cash flow from operations.
In the past 5 years BNN always reported negative net income.
BNN had a negative operating cash flow in each of the past 5 years.
BNN.DE Yearly Net Income VS EBIT VS OCF VS FCFBNN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

The Return On Assets of BNN (-17.27%) is worse than 85.07% of its industry peers.
BNN has a Return On Equity of -227.22%. This is amonst the worse of the industry: BNN underperforms 89.55% of its industry peers.
Industry RankSector Rank
ROA -17.27%
ROE -227.22%
ROIC N/A
ROA(3y)-10.89%
ROA(5y)-10.5%
ROE(3y)-49.48%
ROE(5y)-41.57%
ROIC(3y)N/A
ROIC(5y)N/A
BNN.DE Yearly ROA, ROE, ROICBNN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

BNN's Gross Margin of 55.60% is amongst the best of the industry. BNN outperforms 86.57% of its industry peers.
BNN's Gross Margin has been stable in the last couple of years.
BNN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.53%
GM growth 5Y-0.08%
BNN.DE Yearly Profit, Operating, Gross MarginsBNN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

More info and screens

3

2. Health

2.1 Basic Checks

BNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BNN has about the same amount of shares outstanding.
BNN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BNN has been reduced compared to a year ago.
BNN.DE Yearly Shares OutstandingBNN.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
BNN.DE Yearly Total Debt VS Total AssetsBNN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -1.15, we must say that BNN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.15, BNN is doing worse than 88.06% of the companies in the same industry.
BNN has a Debt/Equity ratio of 0.74. This is a neutral value indicating BNN is somewhat dependend on debt financing.
BNN has a worse Debt to Equity ratio (0.74) than 67.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Altman-Z -1.15
ROIC/WACCN/A
WACC6.57%
BNN.DE Yearly LT Debt VS Equity VS FCFBNN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 1.85 indicates that BNN should not have too much problems paying its short term obligations.
BNN has a Current ratio of 1.85. This is comparable to the rest of the industry: BNN outperforms 55.22% of its industry peers.
BNN has a Quick Ratio of 1.30. This is a normal value and indicates that BNN is financially healthy and should not expect problems in meeting its short term obligations.
BNN has a Quick ratio of 1.30. This is in the better half of the industry: BNN outperforms 70.15% of its industry peers.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.3
BNN.DE Yearly Current Assets VS Current LiabilitesBNN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

BNN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -69.73%.
The Revenue has decreased by -4.88% in the past year.
Measured over the past years, BNN shows a small growth in Revenue. The Revenue has been growing by 6.74% on average per year.
EPS 1Y (TTM)-69.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-59.45%
Revenue 1Y (TTM)-4.88%
Revenue growth 3Y12.27%
Revenue growth 5Y6.74%
Sales Q2Q%-15.68%

3.2 Future

Based on estimates for the next years, BNN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.82% on average per year.
The Revenue is expected to grow by 5.20% on average over the next years.
EPS Next Y70.76%
EPS Next 2Y41.73%
EPS Next 3Y30.72%
EPS Next 5Y28.82%
Revenue Next Year6.32%
Revenue Next 2Y9.1%
Revenue Next 3Y7.18%
Revenue Next 5Y5.2%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BNN.DE Yearly Revenue VS EstimatesBNN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20M 40M 60M 80M
BNN.DE Yearly EPS VS EstimatesBNN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.2 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNN. In the last year negative earnings were reported.
BNN is valuated quite expensively with a Price/Forward Earnings ratio of 768.32.
BNN's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. BNN is more expensive than 71.64% of the companies in the same industry.
BNN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.60.
Industry RankSector Rank
PE N/A
Fwd PE 768.32
BNN.DE Price Earnings VS Forward Price EarningsBNN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 400 600

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNN.DE Per share dataBNN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BNN does not grow enough to justify the current Price/Earnings ratio.
BNN's earnings are expected to grow with 30.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.73%
EPS Next 3Y30.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BNN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRAIN BIOTECH AG

FRA:BNN (6/30/2025, 7:00:00 PM)

1.94

+0.06 (+3.19%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)04-30 2025-04-30
Earnings (Next)08-28 2025-08-28
Inst Owners12.89%
Inst Owner ChangeN/A
Ins Owners53.72%
Ins Owner ChangeN/A
Market Cap42.39M
Analysts84.44
Price Target5.83 (200.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.48%
PT rev (3m)-14.75%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-316.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 768.32
P/S 0.79
P/FCF N/A
P/OCF N/A
P/B 7.05
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)0
Fwd EY0.13%
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS2.45
BVpS0.28
TBVpS-0.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.27%
ROE -227.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.6%
FCFM N/A
ROA(3y)-10.89%
ROA(5y)-10.5%
ROE(3y)-49.48%
ROE(5y)-41.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.53%
GM growth 5Y-0.08%
F-Score2
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.1%
Cap/Sales 2.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 1.3
Altman-Z -1.15
F-Score2
WACC6.57%
ROIC/WACCN/A
Cap/Depr(3y)77.56%
Cap/Depr(5y)65.96%
Cap/Sales(3y)6.63%
Cap/Sales(5y)6.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-69.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-59.45%
EPS Next Y70.76%
EPS Next 2Y41.73%
EPS Next 3Y30.72%
EPS Next 5Y28.82%
Revenue 1Y (TTM)-4.88%
Revenue growth 3Y12.27%
Revenue growth 5Y6.74%
Sales Q2Q%-15.68%
Revenue Next Year6.32%
Revenue Next 2Y9.1%
Revenue Next 3Y7.18%
Revenue Next 5Y5.2%
EBIT growth 1Y-106.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year300.56%
EBIT Next 3Y88.45%
EBIT Next 5Y70.2%
FCF growth 1Y37.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.57%
OCF growth 3YN/A
OCF growth 5YN/A